Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy  by Moran, N.F et al.
Seizure (2004) 13, 425—433
Epilepsy in the United Kingdom: seizure
frequency and severity, anti-epileptic drug
utilization and impact on life in 1652 people
with epilepsy
N.F. Moran, K. Poole, G. Bell, J. Solomon*, S. Kendall, M. McCarthy,
D. McCormick, L. Nashef, J. Sander, S.D. Shorvon
Institute of Neurology, Queen Square, London WC1N 3BG, UK
KEYWORDS
Epilepsy care;
Seizure severity and
frequency;
Anti-epileptic drugs
Summary Objectives: To describe the clinical characteristics of epilepsy in a rep-
resentative sample of the UK population, including seizure frequency and severity;
overall severity of epilepsy; patterns of anti-epileptic drug (AED) use; and the impact
of epilepsy on patients’ lives. Secondly, to determine if these characteristics differ
according to age. Method: A large, geographically comprehensive survey of people
with epilepsy by means of a postal questionnaire distributed by general practitioners
to 3455 unselected patients receiving AEDs for epilepsy, regardless of age or type of
epilepsy and including all regions of the UK. Data were collected on age and gender;
age of onset of seizures; seizure frequency and severity; AED use and adverse effect
levels; and impact on life of epilepsy. Sub-analyses were performed with stratiﬁcation
by epilepsy severity and age-group. Results: There were 1652 completed replies. The
mean age was 44.2 years; there were 47.2% males, 48.5% females (4.4% not recorded).
The mean age at ﬁrst seizure, 25.1 years, and the mean duration of epilepsy, 19.7
years, were comparable with previous studies. In the preceding one year, 51.7% of
patients had no seizures; 7.9% one seizure, 17.2% 2—9 seizures and 23.2% 10 or more.
Sixty-four percent of patients had epilepsy classiﬁed as mild and 32% severe. There
was a marked and signiﬁcant decrement of seizure frequency with increasing age. The
most commonly used AEDs were carbamazepine (37.4%), valproate (35.7%), phenytoin
(29.4%), phenobarbitone or primidone (14.2%) and lamotrigine (10.3%). Monotherapy
was used in 68% of patients. Patients taking multiple AEDs reported signiﬁcantly higher
levels of adverse effects and worse seizure control. The major impacts of epilepsy on
life were work and school difﬁculties, driving prohibition, psychological and social life.
The impacts listed varied with the epilepsy severity and age. Conclusions: Seizures
remain uncontrolled in up to half of all people with epilepsy in the UK with signiﬁ-
cant impact on work, family and social life. Previously, there has been a deﬁciency
of data on the characteristics of epilepsy in older people, although it is recognized
that the condition is of increasing epidemiological importance in this age group. We
have found clear differences in the clinical characteristics of epilepsy in older people,
particularly that seizure frequency appears to decline with increasing age.
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Introduction
More effective medical and surgical treatments
for epilepsy have led to increasing interest in the
condition and to a drive to improve the quality of
services for people with epilepsy. We have sought
to obtain a comprehensive and accurate proﬁle of
epilepsy in the community with the aim of con-
tributing to the rational development of services.
The data presented were drawn from a national
sample of people with epilepsy and describe the de-
mographic characteristics, severity and frequency
of seizures, the utilization of anti-epileptic drugs
(AEDs) and the impact of epilepsy on patients’
lives. It was collected as part of a research enquiry
into epilepsy services in the UK commissioned by
CSAG (Clinical Standards Advisory Group).1
The severity of epilepsy varies widely and any ac-
curate assessment of the morbidity due to epilepsy
must take this into account. Our ﬁrst aim was,
therefore, to determine the proﬁle of disease
severity in the general population by examining
both seizure severity and frequency. In describing
AED utilization, our main aim was to assess any
changes in the patterns of utilization by compari-
son with previous studies. In particular, consensus
treatment guidelines on polypharmacy and the
choice of ﬁrst line agents were previously found to
have had limited impact.2 We aimed to re-evaluate
these aspects and examine the utilization of the
‘‘new’’ AEDs that have been licensed over the last
decade. In addition to utilization, we sought to de-
termine the severity of adverse effects of AEDs and
their efﬁcacy from the users’ perspective, as these
two factors have been found to be central deter-
minants of the quality-of-life (QOL) in epilepsy.3
The ﬁnal aim of this study was to describe the
impact of epilepsy on patients’ lives from their
own perspective and to test the hypothesis that
the types of impact might signiﬁcantly differ in
different seizure severity groups and different
age groups, as such differences are important for
health care planning.
Method
Case ﬁnding and recruitment
People with epilepsy were identiﬁed through 80
primary care practices, geographically distributed
across the UK. All patients who were being pre-
scribed AEDs for epilepsy (apart from febrile convul-
sions) were included and the sample, therefore, is
representative of the overall population of patients
with epilepsy in the country. The practices dis-
tributed 3455 questionnaires during May—October
1998. The method has been discussed in detail
elsewhere.4
The questionnaire and data analysis
The questionnaire asked about basic demographic
details; the age of onset of epilepsy; severity of
epilepsy; frequency of seizures; AEDs; and the
impact of epilepsy on the patient’s life. Seizure
severity was assessed, in patients with one or
more seizures within the last 12 months, us-
ing the National Hospital Seizure Severity Scale
(NHS3),5 with modiﬁcations in order to allow it to
be self-completed. For children and patients with
learning difﬁculties, the parents or carers were
asked to help complete the form.
Subjects were asked how many drugs they were
taking for epilepsy and asked to list them; they
were asked how well they thought the drugs
controlled their attacks and whether they ex-
perienced any side effects. For the latter two
questions, four ﬁxed responses were offered (for
control: ‘‘Very well’’/‘‘Fairly well’’/‘‘Not very
well’’/‘‘Not at all well’’; and for side effects:
‘‘Severe’’/‘‘Moderate’’/‘‘Minor’’/‘‘None’’). For
quantitative analysis, the answers were scored
from 0 to 3 in steps of one; a group score was ob-
tained by calculating the mean score within the
group. For ease of comprehension, this value was
then scaled to a percentage. For example, all sub-
jects responding ‘‘None’’ for the side effects ques-
tion would result in a score of 0%; conversely, if all
subjects responded ‘‘Severe’’, the score would be
100%. To assess impact on life, patients were asked
to list (free-text) the major impacts of epilepsy on
their life (up to three things).
For analysis of AED utilization, epilepsy sever-
ity, seizure severity and impact on life, the sam-
ple was divided into three age bands: less than 17
years, 17—65 years and over 65 years. The groups
were compared using Chi-squared tests. In addition
to age stratiﬁcation, the impact on life data were
analysed according to epilepsy severity based on
the NHS3 which produces scores between 0 and 27.
Patients with a NHS3 score above 15 were classi-
ﬁed as having severe epilepsy and patients with a
score of 15 or less were classiﬁed as having mild
epilepsy, unless they had more than 10 seizures in
the last 12 months, in which case they were classi-
ﬁed as severe. We did not attempt to assess seizure
severity in subjects who had no seizures within the
preceding 12 months.
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Comparison with previous studies
We compared the distribution of the age at
ﬁrst seizure with four epidemiological studies of
epilepsy in the community. The age bands used to
summarise the data in these studies differed in
each paper and, therefore, to allow comparison
to each, we calculated the age distribution in our
sample using each of four age band groups used.
Ethical approval
Ethical approval was obtained from the North
Thames Region Ethics Committee and from each
Local Research Ethics Committee.
Results
Response rate, demographic features, age of
onset and duration of epilepsy
Of 3455 questionnaires distributed, 1652 (48%) were
returned completed. The details of the patients’
current age, age of ﬁrst seizure and duration of
epilepsy are shown in Table 1; 10.8% were aged up
to 19 years, 23.5% 60 years or over (data missing
for 5.1%). The mean age of onset was 25.1 years
Table 1 Current age, age of ﬁrst seizure and the duration of epilepsy in the sample.
Gender (n = 1652)
Male (%) 47.2
Female (%) 48.5
Not stated (%) 4.4
Age (years) Time groups (years)
Current age (n = 1567) Age at ﬁrst seizure (n = 1520) Epilepsy duration (n = 1446)
<10 (%) 3.6 21.2 28.3
10—19 (%) 7.1 25.2 22.0
20—29 (%) 12.3 13.9 14.6
30—39 (%) 18.0 9.9 11.2
40—49 (%) 15.6 8.0 6.8
50—59 (%) 14.6 5.7 3.1
60—69 (%) 11.4 5.8 1.3
70−79 (%) 9.5 1.8 0.1
≥80 (%) 2.5 0.5 0.1
Not stated (%) 5.1 8.0 12.5
Mean 44.2 25.1 19.7
Quartiles (years)
25th 30 10 6
50th 43 19 16
75th 59 38 30
and the mean duration of epilepsy was 19.7 years.
One-thousand-and-sixty-two (64.3%) patients had
epilepsy classiﬁed as mild and 537 (32.5%) severe;
in the remaining 53 (3.2%), severity could not be
determined due to deﬁciencies in questionnaire
completion.
In the analysis of 1064 cases from four epidemio-
logical studies of epilepsy in the community in the
USA, UK and Italy, there were 48% males and 52%
females. Table 2 shows the distributions of age of
ﬁrst seizure in those studies in comparison with the
present study using adjusted age bands.
Seizure severity and frequency
The details of seizure frequency and seizure sever-
ity are shown in Table 3. There was a marked ten-
dency for seizure frequency to decrease with in-
creasing age which was signiﬁcant comparing all
age groups (χ2 = 80.43, d.f. = 8, P < 0.0001). The
mean NHS3 score in the three age bands differed
signiﬁcantly (Kruskal—Wallis χ2 = 18.10, d.f. = 2,
P < 0.0001).
The prevalence of severe epilepsy decreased with
increasing age. The proportion of patients with se-
vere epilepsy in the youngest group (51%) was signif-
icantly greater than that in the 17—65 years group
(37%) (χ2 = 65.7, d.f. = 1, P = 0.000), which was
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Table 2 The distribution of the age at ﬁrst seizure
in four previous epidemiological studies compared to
the present study.
Age at ﬁrst seizure
Age bands
(years)
Previous
study (%)
Current
study (%)
Annegers et al.17 USA (n = 194)
<5 19.6 13.8
5—14 33.5 24.1
15—24 17.5 21.7
25—34 10.8 11.6
35—44 8.8 10.1
45—54 4.6 6.4
55—64 4.1 7.2
65—74 1.0 3.9
75+ 0.0 1.2
Granieri et al.6 Italy (n = 230)
<1 8.7 3.4
1—4 15.2 10.4
5—9 17.8 9.3
10—14 16.5 14.8
15—19 10.4 12.5
20—39 16.1 26.0
40—59 10.9 14.9
≥60 4.3 8.8
Cockerell et al.18 UK (n = 122)
0—10 31.1 25.7
11—20 24.6 27.5
21—30 18.9 14.1
31—40 3.3 11.0
41—50 7.4 7.5
51—60 4.1 6.8
61—70 8.2 5.3
71—80 2.5 1.6
81+ 0.0 0.5
Hauser and Kurland19 USA (n = 516)
<1 7.9 3.4
1—9 25.0 19.7
10—19 13.6 27.3
20—39 23.3 26.0
40—59 12.2 14.9
60+ 18.0 8.8
signiﬁcantly greater than in the over 65 years group
(17%) (χ2 = 154.1, d.f. = 1, P = 0.000).
Anti-epileptic drug usage
Drug utilization and drug combinations
Subjects were excluded if they did not list how
many AEDs they were taking (1.9%) or they were
not taking any AEDs (1.5%). In the latter case, AEDs
had been discontinued in the interim between case
identiﬁcation and questionnaire completion. In all,
1499 were included (90.7% of the total sample).
The mean number of AEDs being taken was
1.4 (range 1—7, median 1.0). The frequencies of
use of each AED are shown in Table 4. Most sub-
jects (68.0%), were taking a single agent. The
seven most frequent drug regimes accounted
for 1117 (74.5%) subjects: sodium valproate
(336/22%); carbamazepine (320/21.3%); phenytoin
(241/16.1%); phenytoin/phenobarbital (65/4.3%);
carbamazepine/sodium valproate (59/3.9%); lam-
otrigine (49/3.3%); and phenobarbital or primidone
(47/3.1%).
The details of the duration of epilepsy in groups
of subjects on monotherapy taking different agents
are shown in Table 4. In this group, the mean dura-
tion of epilepsy in subjects taking phenobarbitone
or primidone or phenytoin was 24.3 years (range
0—75), in comparison with 13.4 years (range 0—63)
for carbamazepine or valproate, and 9.2 (0—36)
years for lamotrigine or vigabatrin (Kruskal—Wallis
over the three groups, P < 0.0001).
In the 366 subjects taking two AEDs, the most fre-
quent combinations were phenytoin/phenobarbi-
tone (17.8%), carbamazepine/valproate (16.1%),
carbamazepine/phenytoin (8.5%), carbamazepine/
lamotrigne (7.7%), valproate/lamotrigine (7.1%),
phenytoin/valproate (6%) and primidone/phenytoin
(4.6%). These seven combinations accounted for
67.8% of the total number of combinations. In
the group taking three AEDs, there were 56 dif-
ferent combinations which included 16 different
drugs.
Seizure control and adverse effects of AEDs
Most subjects were satisﬁed with their seizure con-
trol (Table 5); 67.7% responded ‘‘Very well’’, 25.3%
‘‘Fairly well’’, 5.2% ‘‘Not very well’’ and 1.8% ‘‘Not
very well at all’’.
When asked about the severity of adverse effects,
58.2% responded ‘‘None’’, 28.9% ‘‘Minor’’, 11.2%
‘‘Moderate’’ and 1.6% ‘‘Severe’’. The scores for ad-
verse effects are shown in Table 5.
For patients taking a single agent, the reported
severity of adverse effects and duration of epilepsy,
with stratiﬁcation by the drug being taken are
shown in Table 6. The mean duration of epilepsy in
patients on phenobarbitone was signiﬁcantly higher
than in the case of each of the other AEDs shown
(Kruskal—Wallis over all ﬁve groups, P < 0.0001).
Impact on life
One-thousand-two-hundred-and-thirty-nine pa-
tients responded, listing between one and three
impacts (median = 2, total 2576). These are
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Table 3 Seizure frequency and severity in different age bands.
Age group (years)
<17 17—65 >65 Total
Number of seizures in the last 12 months (percent of patients)
0 28.3 51.0 66.4 51.7
1 3.1 7.5 9.7 7.9
2—9 28.3 17.1 12.7 17.2
10—99 27.6 18.1 10.8 17.4
100 12.6 6.3 0.4 5.8
Number of patients (n) 127 1152 268 1630
Seizure severity (mean NHS3 score)a
Range of scores 1—24 1—26 3—24 1—26
Mean score 13.6 14.5 12.9 14.2
Percentiles
25 9.3 10.0 8.0 10.0
50 14.0 16.0 13.0 15.0
75 19.0 19.0 17.0 19.0
Number of patients (n) 64 485 72 652
Patients were included in the ﬁrst part of the table if they responded to the question on seizure frequency; they
were included in the second part if they had one or more seizures in the last 12 months and the NHS3 was calculable.
aExcluding patients who had no seizures in the last 12 months.
Table 4 The frequency of AED use in 1499 patients.
AED All respondents Monotherapy
n (%) n (%) Duration of epilepsy (years)
n Mean Range
Carbamazepine 560 (37.4) 320 (31.4) 277 15 0—63
Sodium valproate 535 (35.7) 336 (33.0) 308 12 0—61
Phenytoin 441 (29.4) 241 (23.7) 204 21 0—74
Lamotrigine 154 (10.3) 49 (4.8) 43 9 0—36
Phenobarbital 155 (10.3) 47 (4.6) 40 36 0—75
Primidone 58 (3.9) 12 (1.2) 10 38 26—55
Diazepam 37 (2.5) 2 (0.2) 1 19
Gabapentin 33 (2.2) 1 (0.1) 1 4
Clobazam 33 (2.2) 0 (0.0) — — —
Vigabatrin 31 (2.1) 5 (0.5) 5 12 4−29
Clonazepam 26 (1.7) 2 (0.2) 2 19 10—28
Topiramate 26 (1.7) 1 (0.1) 1 3
1499 1019
For the respondents on monotherapy, statistics on the duration of epilepsy are shown. As not all subjects responded
to the question on the age at ﬁrst seizure, the numbers shown are less than the total numbers on monotherapy.
AEDs taken by less than 1% of subjects are not shown.
summarized in Table 7. Themost notable difference
between patients with mild and severe epilepsy
was, in patients over 16 years old, the frequency
of ‘‘driving ban’’ which was stated by 48% in the
mild group in comparison with 28% in the severe
group. The main impacts in adults of all ages were
similar, with driving, work, psychological and social
life being the commonest ones.
Discussion
This study was based on a large sample across the
UK and patients with epilepsy regardless of aeti-
ology, duration or age were included. Three fac-
tors, however, may have somewhat reduced the
representativeness of the sample. Firstly, a propor-
tion of the subjects will have been misdiagnosed as
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Table 5 Polypharmacy, seizure control and adverse effects of AEDs.
Number of drugs
being taken
Number (%)
of subjects
Mean score
Subjective satisfaction with
seizure controla (%)
Subjective severity of
adverse effectsa (%)
1 975 (65.0) 90.4 15.7
2 346 (23.1) 81.6 22.3
3 91 (6.1) 68.5 34.4
4 16 (1.1) 54.2 45.8
Total 1428 86.4 18.8
aSee the Method section for explanation of scoring. A higher score indicates a greater degree of satisfaction with
control or a greater severity of adverse effects. In each row, the range of scores for both the control and adverse
effects was 0—100%.
having epilepsy. In previous studies, estimates of
the proportion of patients misdiagnosed have var-
ied, but, as this was an observational study, were
not in a position to conﬁrm the diagnosis.6 Secondly,
case ascertainment was based upon AED prescrip-
tion and therefore people with epilepsy who were
not taking AEDs will have been missed but this pro-
portion is likely to be small.7 As the primary aim
of this study was to obtain the users’ perception of
epilepsy services, we excluded patients who were
not taking AEDs and, therefore, generally not ac-
cessing epilepsy services. Lastly, as expected from
a postal questionnaire, the response rate was about
50%. Because of the requirement to maintain pa-
tient conﬁdentiality, we were not able to obtain
details of non-responders. However, the age and
gender distribution and drug utilization in our sam-
ple conform to previous epidemiological studies of
epilepsy, providing indirect evidence supporting the
representative nature of our sample.
The severity of epilepsy in the community
Around half of the sample reported no seizures
within the preceding twelve months. This is a
Table 6 The severity of adverse medication effects reported by subjects on monotherapy.
AED Adverse effect score (%) Duration of epilepsy (years)
n Mean Mean Range
Carbamazepine 268 16.7 14.6 0—63
Sodium valproate 300 16.5 12.6 0—61
Phenytoin 198 13.8 21.0 0—61
Lamotrigine 41 31.7 9.0 0—36
Phenobarbital 39 4.3 35.8 0—75
Total 846 16.1 16.1 0—75
broadly similar proportion to that found in pre-
vious studies.8 Although seizure severity was sig-
niﬁcantly lower in over 65 compared to younger
adults, this difference was small and not of clear
clinical signiﬁcance. However, there was a marked
tendency for seizure frequency to decrease with
increasing age. It is impossible to determine, from
a cross-sectional study, if this reﬂects the natural
history of epilepsy or its different predominant
aetiologies in different age groups. Probably both
factors play a role. Whatever the reasons, this is
obviously an important point when planning service
provision, as patients in remission on treatment
have quite different needs from those with ongoing
epilepsy.
Anti-epileptic drug utilization
The pattern of utilization of AEDs for epilepsy in
the community has received relatively little atten-
tion. Roberts et al.’s9 analysis of AED utilization in
the UK was based upon the overall prescription of
AEDs in primary care, and would, therefore, have
included prescriptions for conditions other than
epilepsy, such as pain and psychiatric disorders,
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Table 7 The patients’ perspective on the main impacts on their lives due to epilepsy, with stratiﬁcation by age
and seizure severity.
Seizure severity
Mild Severe
Impact Percent of
all patients
Impact Percent of
all patients
16 years (patients = 33; impacts = 61) (patients = 54; impacts = 121)
School life/education 36 School life/education 33
Psychological 27 Psychological 31
Social life 24 Social life 30
Dangerous sports/sports 18 Dangerous sports/sports 15
Need to take tablets 15 Supervision 11
Sleep 9 Sleep 11
None 9 Play 7
Learning difﬁculties 9 Need to take tablets 7
17—65 years (patients = 568; impacts = 1140) (patients = 347; impacts = 842)
Driving ban 48 Work 51
Work 36 Psychological 35
Social life 19 Social life 32
Psychological 18 Driving ban 28
None 11 Supervision 10
Loss of conﬁdence 8 Independence 9
>65 years (patients = 127; impacts = 191) (patients = 28; impacts = 57)
Driving ban 32 Driving ban 39
Psychological 19 Psychological 29
None 19 Seizures 21
Work 14 Work 21
Bad memory 9 Social life 14
— Loss self-conﬁdence 11
— Mobility 11
— Supervision 11
Social impacts include things such as fear of being alone, stress and acceptance of having epilepsy. ‘‘None’’ means
that the respondent stated that they did not perceive any impacts on their life; it does not refer to non-responders.
which now a account for a signiﬁcant proportion of
prescriptions for all AEDs. Lambie et al., for exam-
ple, found that 9.4% of prescriptions for AEDs were
for conditions other than epilepsy.10
In order to assess any changes in the utiliza-
tion of AEDs for epilepsy, the most relevant study
to compare the current one with is that of Hart
and Shorvon’s2 which described AED utilization in
1051 patients with epilepsy, drawn from primary
care in the UK in 1989. Sixty-ﬁve percent were on
monotherapy, the most frequently used drugs being
phenytoin (33%), carbamazepine (30%), valproate
(25%) and phenobarbital (9%). In the present study,
the proportion of patients on monotherapy was
similar (69%) but there was considerable difference
in the agents used. Valproate and carbamazepine
were the most commonly used drugs (33 and 31%)
in monotherapy and the use of phenytoin (24%)
and phenobarbital (5%) appears to have fallen
markedly. Hart and Shorvon’s found that these four
drugs accounted for 97% of those used in monother-
apy whereas they accounted for 94% in our study,
suggesting a modest impact of the ‘‘new’’ AEDs.
Phenytoin and phenobarbital are not generally
recommended as ﬁrst line agents in epilepsy and
fall in their use most likely reﬂects an increased
awareness of this amongst doctors.
The duration of epilepsy in the subjects on
monotherapy with phenobarbital, phenytoin or
primidone, which are no longer recommended as
ﬁrst line treatment, was signiﬁcantly greater (24.4
years) than that in subjects on monotherapy with
carbamazepine or valproate (13.4 years). This also
suggests that recent practice has changed in accor-
dance with recommendations.
In common with other studies, we found a
clear increase in the severity of adverse effects
with increasing number of agents used.11 This
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underlines the desirability of monotherapy, partic-
ularly as adverse effects are a major component in
the diminishment of QOL in people with epilepsy.
In particular, the combination of phenytoin and
valproate should be avoided because of the danger
of chronic phenytoin toxicity.12 The data on the
severity of adverse effects associated with individ-
ual agents should be interpreted with caution as
the study was cross-sectional and the data cannot
be taken as representative of the general adverse
effect proﬁles of AEDs. Phenobarbital monother-
apy was associated with a lower adverse effect
score than was monotherapy with carbamazepine,
valproate, phenytoin or lamotrigine but the mean
duration of epilepsy in the subjects on phenobar-
bital monotherapy was signiﬁcantly longer than for
the other four AEDs. These subjects may well have
been comprised largely of a self-selecting group
of individuals tolerant to the agent. Conversely,
the high level of adverse effects associated with
lamotrigine may arise from a higher proportion of
patients having been on it for a relatively short pe-
riod, but many may subsequently discontinue the
drug due to adverse effects.
The impact of epilepsy on patients’ lives
The shift of emphasis in health service planning
towards the users’ perspective has driven the de-
velopment of QOL measurement, particularly for
chronic conditions. Several QOL measures have
been developed speciﬁcally for epilepsy and have
been applied to different patient groups, although
mostly to patients with severe epilepsy.13,14 It has
been found that QOL, particularly in psychological
and psychosocial domains, is markedly diminished
in patients with active epilepsy although it may
be high in those with inactive epilepsy.15 Seizure
frequency and type and adverse effects of AEDs
are important contributors to QOL impairment.3
In the current study, we did not attempt to mea-
sure QOL as this was not feasible for a large cohort
within the resources available. We asked patients
to list, without prompts, the major impacts from
their perspective. Whilst this is a simple approach,
it has the advantages of being independent of the
content validity of QOL measurements and, in pre-
vious studies, has been found to generate clearly
deﬁned areas of distress related to epilepsy.16
In all age groups and severity groups, restriction
of work/schooling were amongst the most fre-
quently stated impacts. This is in accord with previ-
ous work which has shown that people with epilepsy
suffer from excessive unemployment and limitation
of choice and advancement in the workplace. In
adults, driving was the second most prominent im-
pact. It was, however, signiﬁcantly less frequently
listed by patients with severe epilepsy compared
to those with mild epilepsy. The principal need to
drive arises from the desire to achieve economic
and social independence. It seems likely, that, in
patients with severe epilepsy, these aspects may
be so severely limited by other consequences of
the condition that driving is less of a concern.
Epilepsy affects abut one in 150 people, of all
ages and backgrounds. Our large population-based
survey in the UK shows that almost half of all people
currently on anti-epileptic drugs continue to have
seizures, with continued impact of work, family and
social life. Better medical care might improve the
lives of people with epilepsy by achieving better
seizure control through rational use of drugs and
surgery.
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